ENANTA PHARMACEUTICALS, INC. (NASDAQ:ENTA) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.
On February 6, 2019, Enanta Pharmaceuticals, Inc. announced via press release its results for the fiscal quarter ended December 31, 2018. A copy of Enanta’s press release is hereby furnished to the Commission and incorporated by reference herein as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
ENANTA PHARMACEUTICALS INC Exhibit
EX-99.1 2 enta-ex991_6.htm EX-99.1 enta-ex991_6.htm Exhibit 99.1 For Immediate Release Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter and Three Months Ended December 31,…
To view the full exhibit click here
About ENANTA PHARMACEUTICALS, INC. (NASDAQ:ENTA)
Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease areas, including non-alcoholic steatohepatitis, respiratory syncytial virus and hepatitis B virus. Its product candidates include Paritaprevir (ABT-530), Glecaprevir (ABT-493), EDP-494 and EDP-239. Its paritaprevir is a protease inhibitor designed for use against hepatitis C virus (HCV). AbbVie Inc. has co-formulated ABT-493 with its second nonstructural protein 5A (NS5A) inhibitor, ABT-530, and is developing them as its next combination. It has demonstrated in replicon assays that its cyclophilin-targeting inhibitor, EDP-494, is a potent inhibitor of HCV replication in wild-type virus and in virus with resistance associated variants.
